A case study outlined a pediatric case of scalp and nail psoriasis, which was successfully treated with an adalimumab biosimilar and monitored with in vivo reflectance confocal microscopy.
A case study outlined a pediatric case of scalp and nail psoriasis, which was successfully treated with an adalimumab biosimilar and monitored with in vivo reflectance confocal microscopy (RCM).
After 24 weeks of adalimumab therapy, PASI 100—a complete resolution based on Psoriasis Area Severity Index (PASI)—was achieved. To the authors’ knowledge, this is the first case of a pediatric patient with nail and scalp psoriasis successfully treated with adalimumab biosimilar and evaluated with RCM.
The physicians who treated the patient and published the article pointed out that the scalp is the area of the body most frequently affected by psoriasis, and nail psoriasis is also common. Psoriasis of the nail and scalp they said “are difficult to treat and cause severe quality of life impairment.”
Adalimumab, an antibody targeting tumor necrosis factor (TNF) alpha, is approved for treatment of psoriasis in the United States and European Union. After previous therapies, including topical treatment and cyclosporine, had failed, the patient initiated an adalimumab biosimilar.
According to the authors, the 16-year-old male patient had moderate-to-severe psoriasis on the scalp, palms, soles of the feet, and “severe nail involvement.” Before starting adalimumab therapy, the patient had a PASI of 8.6, Psoriasis Scalp Severity Index (PSSI) of 30, and Nail Psoriasis Severity Index (NAPSI) of 160, with 80% of the scalp area and 20% of palms and
soles of the feet affected.
Reflectance Confocal Microscopy for Evaluation of Psoriasis Severity
According to the authors, in vivo RCM “performs a noninvasive, real-time evaluation of the skin, from the epidermis to the papillary dermis, being therefore a useful tool to analyze psoriasis treatment response.”
They noted that RCM has been used to evaluate a variety of dermatologic conditions, including skin cancers and inflammatory skin conditions. They cited previous research suggesting the use of RCM for evaluating psoriasis severity could detect “not only clinical but also subclinical
changes,” and a previous study that evaluated improvement of psoriasis using RCM, but did not include scalp and nail lesions.
Improvement Following Adalimumab Biosimilar Treatment
After 12 weeks of treatment, “significant improvement was observed” based on both clinical examination and RCM. The authors reported that PASI 75 (75% reduction of baseline PASI) and PSSI 90 (90% reduction of baseline PSSI) were reached by 12 weeks. Body surface area had decreased from 9.5% to 1%. The patient's NAPSI score had decreased from
160 to 14. After 24 weeks of adalimumab treatment, PASI 100 was achieved, and the patient's nail psoriasis was “completely resolved.”
At 12 weeks, evaluation with RCM “confirmed the improvement of scalp and nails conditions but failed to show a normal conformation.” However, at 24 weeks, “RCM confirmed resolution of the lesions.” Psoriasis resolution was also confirmed by dermoscopy.
The authors said their findings support the use of RCM as “a promising instrument for monitoring nail and scalp psoriasis,” adding that RCM could provide early diagnosis prior to clinical signs, “making a timely therapeutic intervention possible.”
Reference
Megna M, Villani A, Potestio L, Camela E, Fabbrocini G, Ocampo-Garza SS. Adalimumab biosimilar in a pediatric patient: clinical and in vivo reflectance confocal microscopy evaluation. Dermatol Ther. 2022;35(9):e15679. doi:10.1111/dth.15679
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.